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ABSTRACT
Objectives: Grade 3 endometrioid adenocarcinomas (G3 EAC), type two endometrial carcinomas (Type 2 EC), and also 
uterine carcinosarcomas (UCS) are considered as high-grade endometrial adenocarcinomas. The aim of this study was to 
compare the clinicopathologic features and survival of patients with UCS, G3 EAC, Type2 EC.
Material and methods: We included two hundred and thirty-five patients in this study. Patients were divided into three 
groups according to the type of tumor as uterine G3 EAC (group 1, n = 62), Type 2 EC (serous, clear and mixed types; group 2, 
n = 93), and UCS (group 3, n = 80). We compared the groups according to age, initial symptom, surgical approach, stage, 
myometrial invasion (MI), lymph node invasion (LNI), lymphovascular space invasion (LVSI), adjuvant therapy, and survival. 
When comparing the survival outcomes the Kaplan-Meier analysis was performed.
Results: The groups were similar according to age, menopausal status, nulliparity, initial symptoms, stage, LVSI, and LNI. 
Positive cytology was determined significantly more in group 3. There was a significant difference between the groups in 
terms of myometrial invasion degree. Optimal cytoreduction was similar among the groups. The primary adjuvant treat-
ment was chemotherapy for UCS and Type2 EAC whereas radiotherapy was the main adjuvant treatment for G3 EAC. There 
were no significant differences among the groups according to overall survival (OS) (p = 0.290).
Conclusions: Although the survival difference among the groups can not be revealed, these patients have different clinical 
and pathological features and they should be considered as different groups.
Key words: endometrial cancer; high-grade endometrioid adenocarcinoma; overall survival; uterine carcinosarcoma; type 
2 endometrial cancer
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INTRODUCTION
Endometrial cancer is the most common gynecologi-
cal cancer according in developed countries [1]. Today, 
the diagnosis and classification of endometrial cancer is 
mainly based on morphological features and, when nec-
essary, evaluation by immunohistochemical methods. 
The management of patients is decided based on the risk 
groups evaluated according to their clinical and pathological 
features [2]. Although surgical treatment is the basis of the 
treatment, adjuvant therapy (radiotherapy, chemotherapy 
and sometimes together) is recommended for patients at 
high risk [3]. There may be some problems, particularly in 
the management of patients with high-grade endometrial 
cancer (HGEAC). Grade 3 endometrioid adenocarcinomas 
(G3 EAC), type 2 adenocarcinomas (Type 2 EC), and also uter-
ine carcinosarcomas (UCS) are considered as high-grade en-
dometrial adenocarcinomas. Soslow et al [4]. recommends 
moving toward a binary scheme to grade endometrial en-
dometrioid carcinomas by considering International Federa-
tion of Gynecology and Obstetrics defined grades 1 and 
2 tumors as “low grade” and grade 3 tumors as “high grade.” 
One thing is for sure that patients with high-grade carcino-
mas are at risk for recurrence and death [5]. Endometrial 
cancer is divided into two groups , type 1 and 2, according 
to their etiopathogenesis, clinical and pathological features 
by Bockman [6]. While endometrioid tumors constitute the 
type 1 group, non-endometrioid tumors (serous, clear cell 
and mixed) are accepted in type 2. Although advances in 
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the classification and management of endometrial cancer 
according to its molecular characteristics are very current 
[7–9], Bockman’s classification is still widely used due to its 
practical meaning [2, 3]. Approximately 15% of all cases are 
described in the high-risk group and mainly consisted of 
G3 EAC and type 2 non-endometrioid tumors [10]. Above 
50% solid growth of endometrial neoplasm was defined 
as G3 EAC. UCS (malignant mixed mullerian tumors) are 
biphasic tumors (both carcinoma and sarcomatous) tumors 
with poor prognosis should be considered as an HGEAC [11]. 
Endometrial cancer is a heterogeneous group of cancer, 
not only in histopathological types but also in subgroups 
[12]. While there are many studies comparing type 1 and 
2 endometrial cancer at molecular and histopathological 
levels [13–17], there are few studies comparing HGEAC in 
itself according to clinical features and prognosis [18–22]. 
The studies in the literature generally involve comparing 
the two groups, such as UCS vs G3 EAC. Therefore, we aimed 
to compare the clinicopathologic features and survival of 
patients with G3 EAC, Type2 EAC, and UCS.
MATERIAL AND METHODS
This study was performed by examining the data of 
235 patients who were operated on in our clinic and had 
their follow-up between January 1996 and December 
2016. Patients whose pathological examination was not 
performed in our faculty and who were not followed-up 
on in our clinic were excluded. There were 62 patients were 
in the G3 EAC group, 93 patients were in the type 2 EC 
and 80 patients were in the UCS group. Type 2 EC group 
consisted of 24 patients with serous EC, 16 patients with 
clear cell EC, and 53 patients with mixed type. The patients 
were evaluated in terms of age, main symptom (presenting 
symptom) menopause status, medical history (the previous 
cancer history and co-morbidity), surgical history (laporos-
copy or laparotomy, in terms of omentectomy, bowel resec-
tion, and lymph node dissection), whether they achieved 
optimal cytoreduction and whether they performed sec-
ondary cytoreductive surgery due to recurrences. Stage, 
the degree of MI (It was separated as less than 50% and 
more), LNI, LVSI, the presence of positive cytology, the 
type of adjuvant treatment (radiotherapy, chemotherapy 
or both), and survival outcomes [disease free-survival (DFS) 
and overall survival (OS)] were evaluated and compared 
among the groups. The staging was performed according 
to the FIGO 2009. The primary surgical procedures were 
laparotomic or laparoscopic total hysterectomy and bilateral 
salpingo-oophorectomy (TH + BSO) and pelvic/para-aortic 
lymphadenectomy with or without omentectomy. A maxi-
mum residual tumor of < 1cm was the optimal cytoreduc-
tion. For high-risk patients, chemotherapy and radiotherapy 
was administered for systemic and locoregional control, 
respectively. Follow-up was performed in three months 
intervals within the first year, and then six months intervals 
up to five years. The time (months) between the surgery/ 
/diagnosis and death or last follow-up was defined as OS. 
The time (months) from surgery to disease progression or 
last follow-up was defined as DFS.
Data were analyzed using the SPSS software version 
20.0 (IBM, Armonk, NY, USA). Comparisons the three groups 
were performed using the one-way ANOVA test. Bonferroni 
correction was used. A Chi-Square test was used for categori-
cal data analysis. Results were demonstrated as mean ± SD 
and median (min-max), and n (%). All recorded p-values are 
two-tailed. With the Kaplan–Meier method, the effects of 
clinical variables and histopathologic subtypes on survival 
data were analysed. The differences of the survival curves 
were evaluated using the log-rank test. 
RESULTS
Two hundred thirty-five patients were eligible for the 
study, 62 of them were in the G3 EAC (group 1) , 93 were in 
the type 2 EC (group 2), and 80 were in the UCS (group 3). 
There were no significant differences between the groups in 
terms of age. In groups, abnormal uterine bleeding was the 
main symptom, while abdominal distension was high in the 
group 2. We did not find a statistically significant difference 
between the groups regarding the menopausal status and 
medical history. But there were seven patients with history 
of another cancer, four of them had breast cancer and two 
of them had colon cancer and one of them had skin cancer 
in the group 3. Laparoscopic surgery was performed more 
in groups 1 and 2 than in group 3 (p = 0.002). Omentec-
tomy rates were also significantly different between the 
groups (p = 0.001). Lymph node dissection rates were simi-
lar (p = 0.080). Rates of bowel resection, reaching optimal 
surgery, and secondary cytoreductive surgery were similar 
among the groups. In total, 26 patients underwent bowel 
resection. Secondary cytoreductive surgery was performed 
in 30 patients due to recurrence. The comparison of the 
groups in terms of demographic features and surgical ap-
proach is summarized in Table 1.
The groups were similar in terms of stage, LVSI and nodal 
involvement (p = 0.340, 0.071, 0.139; respectively). In the 
group 2, endometrium-limited polypoid tumors without 
myometrial invasion are more than the others (p = 0.001). 
Positive cytology is higher in the group 2 and 3 than the 
group 1 (p = 0.024). Adjuvant treatment options were sig-
nificantly different between groups. While chemotherapy 
was the first adjuvant option in groups 2 and 3, patients in 
group 1 received radiotherapy as the first adjuvant option.
Mean OS was 50 months for group 1, 45 months in 
group 2, and 35 months in group 3. The difference be-
tween the groups in terms of OS did not reach a signifi-
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Table 1. The comparison of the groups in terms of demographic features and surgical approach
 Studied groups 
 (Mean ± SD, n%)
 Group 1
 HGEAC



















































Omentectomy (infracolic or total)) 26 (42%) 63 (68%) 42 (53%) 0.001
Colon resection 4 (6%) 8 (9%) 14 (18%) 0.169
Optimal cytoreduction 46 (74%) 73 (78%) 74 (93%) 0.214
Secondary cytoreduction surgery 8 (13%) 15 (16%) 7 (9%) 0.115
HGEAC — high grade endometrioid adenocarcinoma; Type 2 EC — type 2 endometrial cancer; UCS — utrerine carcinosarcoma; PLN — pelvic lymph node dissection; 
PPALND — pelvic-paraaotic node dissection; p* — the p values obtained by comparing all 3 groups using the one-way Anova test
cant level (p = 0.290). DS was significantly different among 
the groups (p = 0.019). The mean DFS was found to be 
45 months in group 1, 29 months in group 2 and 19 months 
in group 3 (Tab. 2.). Figure 1 shows the prognosis of the 
groups in terms of OS. Figure 2 shows the prognosis of the 
groups for DFS.
DISCUSSION
In our study, we showed that all three groups were simi-
lar according to OS, whereas there was a difference between 
the groups in terms of DFS. The G3 EAC group had the best 
DFS, while the worst group was the UCS group. The number 
of studies comparing these groups is also limited. Because 
the frequency of this group of tumors is low, and the results 
of the current studies’ results are limited and contradictory 
due to few cases numbers, difficulties in pathological evalu-
ation and identification, inclusion criteria, and variety of 
adjuvant treatments. 
When we look at studies comparing G3 EAC and type 
2EAC, there are different results in terms of prognosis. Aye-
ni et al. compared 119 G3 EAC cases with 211 serous and 
40 clear cell EAC [23]. They didn’t show any differences 
with the prognosis in the groups. Myometrial invasion 
degree was found higher in the G3 EACs group like our 
results, but stage 4 disease was found higher in serous 
EC. Hamilton et al. [24] perform the widest comparison 
(serous n = 1453, clear cell n = 391, and G3 EAC n = 2316) 
using Surveillance, Epidemiology, and End Results Pro-
gram (SEER data). This study showed that serous and clear 
cell type predict for lower survival rate. In another study 
comparing 52 patients with G3 EAC with 87 patients with 
serous EC, the prognosis in serous EC was reported to be 
worse than G3 EAC [25]. Similarly Crisano et al. showed 
that even in the early stage, type 2 ECs (serous n = 53, 
clear cell n = 18) have a higher recurrence rate and worse 
prognosis than other ECs (n = 509), including G3 EACs 
(n = 90) in accordance with the result of our study [26]. 
McGunigal et al. [27] also demostrated that G3 EAC had 
better prognsosis. Unlike the results of this study, there 
is also a study showing that serous and clear cell EC 
have better prognostic features similar to G3EAC for only 
stage 1 [27]. Soslow et al. [28] performed a comparison 
analysis among the G3 EAC (n = 89), serous EC (n = 61), 
and clear cell EC (n = 37) cases and they reported that 
there was no significant difference in the prognosis be-
tween these groups.
If we look at the studies comparing UCS with other 
HGEAC, our study showed a poorer prognosis in UCS. The 
groups were similar in terms of OS, however, in accordance 
with the literature, DFS was significantly shorter in UCS 
than the others groups. Previous studies compared the 
prognosis of UCS with G3 EAC [19–21, 29] and high-risk 
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endometrial cancer type including serous, clear, HGEAC [22, 
30–32]. In a large scale study, a poorer five-year survival rate 
was found for all stages of UCS [19]. However, in another 
study similar results were reported for UCS with others [22]. 
There are four studies in the literature comparing the 
G3 EAC, type 2 EC, and UCS [22, 30, 34, 35]. Felix et al. com-
pared the 81 UCS, 254 G3 EAC, 73 clear cell EC, and 147 serous 
EC cases. They showed similar results for the OS and recur-
Figure 1. The comparison analysis of overall survival (OS) of 
the studied groups (ucs: uterine carcinosarcoma; Type 2 and: 
Type 2 endometrial cancer; Grade 3 and: Grade 3 endometrioid 
adenocarcinomas)
Figure 2. The comparison analysis of disease-free survival (DFS) 
of the studied groups (ucs: uterine carcinosarcoma; Type 2 and: 
Type 2 endometrial cancer; Grade 3 and: Grade 3 endometrioid 
adenocarcinomas) 
































































































50.0 ± 6.2 45.0 ± 7.3 35.0 ± 7.5 0.290
DS [month] 45.0 ± 6.7 29.0 ± 5.6 19 ± 3.7 0.019
HGEAC — high grade endometrioid adenocarcinoma; Type 2 EC — type 2 endometrial cancer; UCS — utrerine carcinosarcoma; LVSI — lymphovascular space invasion; OS 
— overall survival; DFS — disease free survival; p*— The p values obtained by comparing all 3 groups using the one-way Anova test
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rence free survival among the groups by the stratified stages 
[22]. The other study was performed by Amant et al. [30]. 
They evaluated 50 cases with G3 EAC, 54 cases with serous 
or clear cell EC, and 33 cases with UCS. The worst prognosis 
in this study was found in the UCS group, consistent with 
the results of other studies [34, 35]. However, in our study, 
this difference did not reach a statistically significant level. 
Amant et al. reported that the LNI was found higher in the 
UCS group than the others. There is also a significant dif-
ference among the groups in terms of LNI in the Felix et al. 
study [26]. LNI was not found different among the groups 
in our study. We found the positive cytology rate higher in 
the type 2 EC (20%) and UCS (18%) group compared to the 
G3 EAC (2%) group (p = 0.024). This rates were reported as 
30% for UCS, 18.6% for type 2 EC, and 11.6% for G3 EAC 
group in the Amant et al.’s study (p = 0.14) [30]. While there 
was no difference in our study in terms of stage, the other 
two studies found a significant difference for the stages 
among the groups [22, 30]. In our study, there was a sig-
nificant difference between groups in terms of adjuvant 
treatment options. While chemotherapy was the main ad-
juvant option in the type 2 EC group and the UCS group, 
radiotherapy was the main adjuvant treatment option in 
the G3 EAC group. Similar results were reported in the Felix 
et al study. But Amant et al. did not evaluated the adjuvant 
therapy option [30]. 
Although we had a relatively good number of cases 
(for only one center), more cases are needed to reveal dif-
ferences in prognosis. Our evaluation was meant to reveal 
clinicopathological differences not only in terms of prog-
nosis. It would not be appropriate to discuss the results of 
adjuvant therapy in these patient numbers. It is not easy to 
reach a conclusion for the studies on relatively rare group 
tumors. As a matter of fact, heterogeneity is high at the 
molecular level even in a single group [13, 14–17]. Increasing 
molecular studies show that these groups are very different 
tumors and therefore exhibit different clinical and prognosis.
CONCLUSIONS
As a conclusion, We did not show a significant differ-
ence among the groups in terms of prognosis, but there 
were differences among the groups in terms of prognostic 
clinical-pathological features. A better understanding of 
these tumors at the molecular level will allow them to be 
better managed.
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